Virtual Reality Combined With rTMS for the Treatment of Depression : a Randomized Clinical Trial.

NCT ID: NCT03336788

Last Updated: 2017-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-09

Study Completion Date

2019-11-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Depression is a mood disorder affecting an individual in its entirety, altering its emotional and intellectual functioning . The major form of depression is the most common psychiatric disorder in Western countries. It is considered to be the most expensive psychiatric neurological disease in Europe and is currently treated by different methods.

However, almost a third of depressed patients shows no clinical improvement. Advances in neuroscience and understanding of neuromodulation have enabled the emergence of new treatments such as the repetitive transcranial magnetic stimulation (rTMS) . It consists of modulating the neuronal activity of a targeted brain region through a magnetic field applied by a coil. Even though this form of treatment has proven to be effective, it appears that more than half of depressed patients exhibited little to no response to it.

As brain regions targeted by TMS may also be stimulated beforehand by sensory afferent signals, it was hypothesized that optimizing the effects of TMS with virtual reality is possible through the activation of these brain regions with sensory stimuli holding emotional valence (images, sounds) while using TMS concomitantly. Based on this new research premise, the investigators propose, in the context of an open and controlled clinical trial, to use a new media entitled virtual reality for displaying interactive virtual environments with positive emotional valence ( field of flowers, green valley) to a group of depressed patients undergoing TMS at the same time.

The study will include 66 depressed patients randomly assigned into two groups : TMS and Virtual Reality Versus TMS alone. Any differences in therapeutic efficacy between the two groups will be measured by questionnaires and brain functional imagery. This innovative and therapeutic approach will allow us to better understand the appropriate processes for modulating the neuronal activity in specific brain areas for treatment purposes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

the Treatment of Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TMS

Group Type PLACEBO_COMPARATOR

Transcranial Magnetic Stimulation (TMS - ) MagPro®

Intervention Type DEVICE

20 sessions navigated with Conventional Transcranial Magnetic Stimulation

TMS with virtual reali

Group Type ACTIVE_COMPARATOR

Transcranial Magnetic Stimulation (TMS - ) MagPro®

Intervention Type DEVICE

20 sessions navigated with Conventional Transcranial Magnetic Stimulation

virtual reality for displaying interactive virtual environments

Intervention Type DEVICE

20 sessions navigated with virtual reality

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Transcranial Magnetic Stimulation (TMS - ) MagPro®

20 sessions navigated with Conventional Transcranial Magnetic Stimulation

Intervention Type DEVICE

virtual reality for displaying interactive virtual environments

20 sessions navigated with virtual reality

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Criteria of resistant depression
* Age from 18 to 65 years old included.
* Primary diagnosis of major depression in subjects according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria.
* Informed consent and signed to participate in the study

Exclusion Criteria

* Pregnant woman, parturient and nursing mothers.
* Absence of DSM-5 criteria for depression in subjects.
* Refusal to participate in the study.
* Modification of drug treatment in the month preceding inclusion.
* History of neurological pathology, head trauma or mental retardation.
* Presence of an addictive comorbidity.
* Presence of a major organic pathological.
* Presence of a contra-indication to virtual reality
* Presence of intracerebral ferro-metallic material, cochlear implant, pacemaker
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique Hopitaux De Marseille

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Raphaëlle RICHIERI, PH

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique Hôpitaux de Marseille

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assistance Publique Hôpitaux de Marseille

Marseille, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Raphaëlle RICHIERI, PH

Role: CONTACT

Phone: 491435551

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Raphaëlle RICHIERI, PH

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-A01115-46

Identifier Type: REGISTRY

Identifier Source: secondary_id

2016-21

Identifier Type: -

Identifier Source: org_study_id